Key clinical point: PRS-343, a 4-1BB/HER2 bispecific molecule, demonstrated antitumor activity in patients with heavily pretreated, HER2-positive solid tumors.
Major finding: Of 18 evaluable patients, 2 achieved a partial response and 8 had stable disease.
Study details: A phase 1 study of 53 patients.
Disclosures: The study is sponsored by Pieris Pharmaceuticals. Dr. Ku disclosed relationships with Arog Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Merck, Zymeworks, and Pieris Pharmaceuticals.
Ku GY et al. SITC 2019, Abstract O82.